Nuvectis Pharma is a biopharmaceutical company focused on the development of precision medicines for serious unmet needs in oncology. Its lead candidate, NXP800, is a novel oral small-molecule inhibitor of the heat shock factor 1 (HSF1) pathway, in-licensed from the CRT Pioneer Fund and discovered at the Cancer Research UK Cancer Therapeutics Unit at The Institute for Cancer Research in London. In preclinical studies NXP800 inhibited tumor growth in xenograft models of ovarian clear cell carcinoma (OCCC) and endometroid ovarian cancer. Nuvectis completed a $15 million Series A Preferred Stock financing with institutional and private investors and plans to begin a Phase I trial in patients with advanced solid tumors in Q4 2021, followed by cohorts for OCCC and endometroid ovarian cancers. The company was founded in 2020, is led by industry veterans with drug development experience, and is based in Fort Lee, New Jersey. The CRT Pioneer Fund, managed by Sixth Element Capital, is described as a £70 million specialist oncology investment fund established to bridge cancer drug discovery and early clinical development.

Total raised

$15M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2021